03/25/14 - 01:29 PM EDT
How to promote your stock, Galectin style.READ FULL POST
03/24/14 - 04:17 PM EDT
If you want to understand why your beloved biotech stocks are tanking, you must read Brown's blog post right now. Hell, if you already read Brown's post earlier today, read it again.READ FULL POST
03/24/14 - 11:21 AM EDT
Bubble or not, biotech stocks have been weak all March, erasing gains made in February.READ FULL POST
03/21/14 - 02:02 PM EDT
Investors are spooked that heightened scrutiny over Gilead's Hep C drug will cause a backlash across the entire biotech sector.READ FULL POST
03/20/14 - 05:54 PM EDT
Bloomberg's Drew Armstrong and ISI Group's Mark Schoenebaum discuss Gilead, Sovaldi and the controversy of Medicaid reimbursement.READ FULL POST
03/18/14 - 03:22 PM EDT
When your job is helping MannKind sell stock, it's not hard to be a bull.READ FULL POST
03/18/14 - 11:03 AM EDT
With its Big Pharma partner gone, Prosensa will probably try to conjure a good story to bring in front of the FDA.READ FULL POST
03/14/14 - 08:04 PM EDT
Intercept discloses cardiovascular events reported in a study of the company's fatty liver disease drug.READ FULL POST
03/14/14 - 12:45 PM EDT
Gilead has transformed itself with tremendous success twice already and is now working on plan number three.READ FULL POST
03/14/14 - 10:54 AM EDT
Richard Pearson's expose, published yesterday on Seeking Alpha, pulls back the curtain on the shady world of paid stock touts. It's an excellent, well-researched story, mostly because of the documentation (emails and electronic signatures) Pearson obtained linking executives at Cytrx and Galena Biopharma to the publication of promotional articles under assumed names and without proper financial disclosure.READ FULL POST
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.